Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand/regional name for **Cefixime**, a third-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs). It has expanded Gram-negative coverage compared to earlier generations but limited activity against *Staphylococcus aureus*.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Uncomplicated gonorrhea (cervical, urethral, and rectal)
* Acute bronchitis/exacerbations of chronic bronchitis
## Adult Dosing
* **Respiratory/UTI:** 400 mg daily or 200 mg every 12 hours.
* **Uncomplicated Gonorrhea:** 800 mg orally as a single dose (note: check local resistance patterns and current CDC/regional guidelines for dual therapy requirements).
## Pediatric Dosing
* **Children (> 6 months):** 8 mg/kg/day orally, either as a single dose or divided into two 4 mg/kg doses every 12 hours.
* **Maximum Dose:** 400 mg/day.
## Dose Adjustments
* **Renal Impairment:** If CrCl 21–60 mL/min, administer 75% of the standard dose. If CrCl < 20 mL/min, administer 50% of the standard dose.
* **Hemodialysis:** No supplementary dose required.
## Contraindications
* Hypersensitivity to cefixime or other cephalosporins.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins or other beta-lactams.
## Adverse Effects
* **Common:** Diarrhea (frequent), abdominal pain, nausea, dyspepsia.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (rash/urticaria), rare instances of Stevens-Johnson syndrome or toxic epidermal necrolysis.
## Key Drug Interactions
* **Warfarin:** May increase INR and bleeding risk by altering gut flora (vitamin K synthesis).
* **Probenecid:** May increase serum concentrations of cefixime by reducing renal tubular secretion.
## Monitoring
* Monitor for signs of superinfection (e.g., persistent diarrhea suggestive of *C. difficile*).
* Renal function (BUN/SCr) in patients with pre-existing impairment.
* Resolution of clinical symptoms at the site of infection.
## Clinical Pearls
* **Absorption:** Oral suspension may have higher bioavailability than tablets; verify formulation per local pharmacy availability.
* **Spectrum:** Not effective against *Pseudomonas aeruginosa* or methicillin-resistant *Staphylococcus aureus* (MRSA).
* **Administration:** Can be taken with or without food.
* **Local Protocols:** Cefixime monotherapy for gonorrhea is no longer recommended in many jurisdictions due to rising MICs; consult current STD treatment guidelines (e.g., CDC) for mandatory ceftriaxone injectable regimens.
***
**Educational Disclaimer:** This information is for educational purposes and does not substitute for professional medical judgment. Always consult the official package insert, your institution's institutional formulary, or local antimicrobial stewardship guidelines before prescribing or dispensing. Verify all dosages based on the patient's age, weight, and renal function.
